Cantero-Fortiz Y, León-Peña AA, León-González M, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Language: English
References: 17
Page: 63-66
PDF size: 291.76 Kb.

ABSTRACT

Multiple myeloma (MM) is a monoclonal gammopathy known as the malignant proliferation of plasma cells presenting typical complications like hypercalcemia, osteolytic bone lesions, anemia, renal insufficiency, and infections. Central nervous system (CNS) involvement in multiple myeloma, also known as leptomeningeal myelomatosis is uncommon and has been reported only in 1% of patients. Represents a complication of multiple myeloma in which the pathophysiology of migration and proliferation of plasma cell remains unknown. The diagnosis hallmark for this entity is the presence of plasma cells in cerebrospinal fluid (CSF). The reduced number of patients with leptomeningeal myelomatosis makes unclear the optimal therapy for this condition. Intrathecal therapy has shown to be an effective therapy to clear plasma cells from CSF. We present a case of a 40-year-old patient with multiple myeloma and central nervous system involvement on his first relapse, treated with combined therapy.

REFERENCES

1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.

2. Chen CL, Masi-Khan E, Jiang H, Rabea A, et al. Central Nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol 2013;162:483-488.

3. Bladé CJ, Izquierdo SM. Medicina Interna. Gammapatias monoclonales. Farreras-Rozman P1775. 16th ed. España: Elsevier, 2012.

4. Maldonado JE, Kyle RA, Ludwig J, Okazaki H. Meningeal myeloma. Arch Intern Med 1970;126:660-663.

5. Ben-Bassat I, Frand UI, Isersky C, Ramot B. Plasma cell leukemia with IgD paraprotein. Arch Intern Med 1968;121:361-364.

6. Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999;62:228-233.

7. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Perez-Romano B, Marin-Lopez A, Delgado-Lamas JL. Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignances can be performed entirely on an outpatient basis. Am J Hematol 1998;58:161-164.

8. León-Ruiz M, Benito-León J, Sierra-Hidalgo F, Garcia Soldevilla MÁ, et al. First case described of isolated, complete and fluctuating cranial nerve III palsy heralding multiple myeloma. Rev Neurol 2015;60:115-119.

9. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999;113:73-77.

10. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005;80:1371-1382.

11. Marjanović S, Mijusković Z, Stamatović D, Madjaru L, et al. Multiple myeloma invasion of the central nervous system. Vojnosanit Pregl 2012;69:209-213.

12. Buda G, Orciuolo E, Galimberti S, Ghio F, Petrini M. VDTPACE as salvage therapy for heavily pretreated MM patients. Blood 2013;122:5377.

13. Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Heaematol 2008;80:1-9.

14. Avigan D, Rosenblatt J. Current treatment for multiple myeloma. N Engl J Med 2014;371:961-962.

15. Harousseau JL, Moreau P. Autologous hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-2654.

16. Muscal J, Sun Y, Nuchtern J, Dauser RC, et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol 2012;69:943-947.

17. Fasssas AB, Muwalla F, Berryman T, Benramdane R, et al. Myeloma of the central nervous system: association with high risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002;117:103.